Fletcher trait plasma failed to generate kinin and developed only a small amount of arginine esterase activity at an abnormally slow rate following surface activation. Neither defect was due to a deficiency of Hageman factor (HF, factor XII) or kininogen or to an excessively rapid inactivation of evolving kinin. Pyrex pretreated with Fletcher trait plasma did not generate kinin normally in fresh normal plasma. Fractions rich in prekallikrein prepared from normal, HF-deficient, or plasma thromboplastin antecedent (PTA)-deficient plasma developed kallikrein activity by direct activation during incubation with trypsin or HF fragments formed by digesting partially purified HF with trypsin. In contrast, identical fractions of Fletcher trait plasma did not develop this activity. Although this finding suggested that Fletcher trait plasma was deficient in prekallikrein, materials eluted from Celite that had been incubated in Fletcher trait plasma contained both esterase and kinin-generating activities. Celite eluates prepared from normal and Fletcher trait plasma released kinin from partially purified kininogen equally well. This release was blocked by soybean trypsin inhibitor but not by lima-bean trypsin inhibitor. Therefore, although unfractionated Fletcher trait plasma appears to be functionally and antigenically deficient in normal prekallikrein, it may actually contain a different prekallikrein which is activated by exposure to Celite but not by exposure to activated HF or trypsin.
• Study of the plasma from individuals with a congenital deficiency of Hageman factor (HF, factor XII) defined a crucial role for HF in the relationships between the initiation of blood coagulation, fibrinolysis, esterolysis, and kinin formation (1) (2) (3) . In 1965, Hathaway et al. (4) described a family with a new clotting defect (Fletcher trait) which involves the initiation of blood clotting; however, this trait differs from Hageman trait. Hattersley and Hayse (5) have reported three unrelated cases of Fletcher trait. In agreement with Wuepper (6) and Weiss et al. (7) , we have found that surface-mediated fibrinolysis, permeability enhancement, and clotting activity are defective in Fletcher trait plasma (8) . These defects are best explained by the assumption that Fletcher trait plasma is functionally deficient in a prekallikrein which is required for the optimal functioning of activated HF or, alternatively, for the complete activation of HF. The present study indicates that the generation of esterolytic activity and kinin is also defective in unfractionated Fletcher trait plasma, suggesting that this plasma is deficient in a prekallikrein. However, a fraction of Fletcher trait plasma is rich in esterase and kinin-generating activity that resembles that of kallikrein which can be activated in normal plasma. Therefore, Fletcher trait plasma may not actually be deficient in prekallikrein but may simply contain a prekallikrein with different properties from that in normal plasma.
Acid-washed kaolin, ellagic acid, and Enzitetrypsin (0.40 units/mg) were prepared as described previously (8) .
p-Toluenesulfonyl-/-arginine methyl ester, N-benzoyl-Z-arginine methyl ester, <*-tosyl-Mysine methyl ester, and N-a-acetyl-Mysine methyl ester HCI were dissolved in phosphate-buffered saline. Lima-bean trypsin inhibitor, soybean trypsin inhibitor, and Trasylol (preparation A128, Farbenfabriken Bayer AG) were dissolved and diluted in barbital-saline buffer.
One preparation of lyophilized partially purified HF (low-purity HF) contained 13 units/mg protein and was dissolved before use in 1% crystalline bovine serum albumin in barbital-saline buffer. High-purity HF had a specific activity of 52 units/mg protein (8) . One unit of HF is defined as that amount in 1 ml of a pool of normal citrated plasma.
HF fragments were prepared by incubating 3 ml of high-purity HF (4.7 units/ml in barbital-saline buffer containing 10~4M disodium ethylenediaminetetraacetate [EDTA]) and 1.2 ml of Enzite-trypsin (10 mg/ml in barbital-saline buffer) at 37°C for 30 minutes with occasional shaking. After the Enzitetrypsin was removed by centrifugation, the supernatant fluid was filtered through a column of Sephadex G150 (2.6 X 100 cm) equilibrated with 0.15M NaCl in 0.025M Tris-HCl buffer (pH 8 at 4°C) containing 10~4M EDTA; 3-ml fractions were collected at a flow rate of 30 ml/hour. Prekallikrein-activating activity (see Procedure) was eluted about 380 ml after an ovalbumin marker (twice crystallized, Schwartz-Mann, molecular weight 45,000), indicating a molecular weight of approximately 30,000. Pooled fractions (32 ml) were concentrated to approximately 5 ml by placing them in a cellophane dialysis casing immersed in dry Sephadex G75 powder; they contained four prealbumin protein components. Analytic polyacrylamide gel electrophoresis showed that prekallikrein-activating activity was associated with all four of these prealbumin protein components (when replicate gels were cut and eluted), suggesting that these HF fragments are similar to a prekallikrein activator variously called prealbumin activator (10) or PKA (11, 12) . These fragments did not contain significant HF coagulant activity.
Partially purified plasma prekallikrein was extracted from normal human oxalated plasma by tricalcium phosphate adsorption and ammonium sulfate precipitation (20-60% saturation). The prekallikrein was then twice eluted in the initial fractions emerging from a QAE-Sephadex column in solutions of Tris-HCl (pH 8.0, 0.025M) containing 0.05M NaCl, 10~4M N A , H 2 EDTA, and 50 fig hexadimethrine bromide/ml. This solution was also used to equilibrate the column. Next, the prekallikrein was eluated from an SP-Sephadex C50 column equilibrated with sodium acetate (0.05M, pH 5.2) containing 0.15M NaCl and 10~4M Na 2 H 2 EDTA by the addition of a linear gradient of NaCl (from 0.15M to 0.5M) to this buffer. Hexadimethrine bromide (50 /u.g/ml) was included in the buffer solutions through the first elution from the QAE-Sephadex column to inhibit activation of prekal-likrein. This prekallikrein released 49 /uM methanol/ hour mg~' protein in the p-toluenesulfonyl-J-arginine methyl esterase assay with trypsin activation and 13 MM methanol/hour mg" 1 protein without activation, indicating that approximately 25% of the prekallikrein was already activated. The prekallikrein preparation contained no detectable HF, but it did have traces of plasma thromboplastin antecedent (PTA) (less than 0.05 units/ml) and HF-cofactor (13) .
To prepare crude plasma prekallikrein, 1.5 ml of normal, HF-deficient, PTA-deficient, or Fletcher trait plasma was mixed with 0.02 ml of hexadimethrine bromide (5 mg/ml) in 10~2M EDTA and dialyzed overnight against 1 liter of 0.025M Tris-HCl buffer (pH 8) containing 0.05M NaCl and 10" 4 M EDTA. Dialyzed plasma was adsorbed for 10 minutes at 4°C with 15 ml of packed QAE-Sephadex A50 equilibrated with the preceding buffer. After centrifugation at 2,000 g for 10 minutes, the supernatant fluid was used as a crude prekallikrein fraction. Partially purified plasma kallikrein was prepared as described (8) .
Crude Celite 512 2 eluates prepared from citrated or oxalated normal and Fletcher trait plasma and from citrated HF-deficient plasma as described previously (13) contained no fibrinolytic activity and did not form visible clots on incubation with bovine fibrinogen for 48 hours.
A neutral solution of ammonium sulfate, saturated at 4°C, was used to precipitate fractions from plasma which were then extensively dialyzed first against water and then against barbital-saline buffer.
Crude kininogen (heated plasma) used for the assay of kallikreinlike activity was prepared by heating normal plasma to 61°C for 60 minutes (14) . It did not generate kinin activity during incubation with HF fragments (Table 1) .
Partially purified kininogen was prepared by a modification of a previously described method (15) . Human oxalated plasma was adsorbed with tricalcium phosphate, fractionated with ammonium sulfate (20-60% saturation), and then chromatographed successively on QAE-Sephadex A50, SP-Sephadex C50, and Sephadex G150, using buffers containing hexadimethrine bromide (50 /x.g/ml) through the step at which material was eluted from the QAE-Sephadex A50 column. Kininogen was measured on the estrus rat uterus after conversion to kinin by trypsin. The kininogen used (0.75 mg/ml) released kinins on incubation with purified plasma kallikrein or trypsin but not with HF fragments.
Synthetic bradykinin 3 was dissolved at a concentration of 1 /xg/ml in 0.15M NaCl and stored in cellulose nitrate tubes at -70°C. o-Phenanthroline was dissolved at a concentration of 0.01M in barbital-saline buffer and stored at 4°C.
Lysergic acid diethylamide and carboxypeptidase B were dissolved in 0.15M NaCl in stock concentrations of 10~3M and 500 ftg/ml, respectively. Carboxypeptidase B contained 10" 3 M CoCl 2 .
*Gift of Johns-Manville Celite Division, New York. 3 Gift of Sandoz, Inc., Hanover, New Jersey.
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Barbital-saline buffer (pH 7.4) contained 2.76 g of barbital, 7.3 g of NaCI, and 2.06 g of sodium barbital per liter.
PROCEDURE
HF and PTA procoagulant activities were assayed as previously described (16) . Esterolytic activity was assayed by a modification (17) of the method of Siegelman et al. (18) .
Prekallikrein-activating activity was measured esterolytically by incubating 0.1 ml of a test sample with 0.05 ml of partially purified prekallikrein (0.78 mg protein/ml) at 37°C for 30 minutes in 12 x 75-mm polystyrene tubes. After adding 0.05 ml of lima-bean trypsin inhibitor (1 mg/ml), 2 ml of 0 . 0 1 5 M p-toluenesulfonyl-i-arginine methyl ester was added to the tubes and incubated at 37°C for 60 minutes; p-toluenesulfonyl-J-arginine methyl ester hydrolysis was measured as described previously (17, 18) .
Kaolin activation of plasma arginine esterase was tested by a method described by Colman et al. (19) . Plasma (0.15 ml) and kaolin suspension (0.15 ml, 10 mg/ml 0.1M sodium phosphate buffer, pH 7.5, in 0.15M NaCI) were incubated in 12 X 75-mm polystyrene tubes at 25°C. At intervals, 0.2-ml samples were transferred to 13 X 100-mm glass tubes containing 2.0 ml of 0.05M p-toluenesulfonyl-Z-arginine methyl ester in O.lM sodium phosphate buffer (pH 7.5) in 0.15M NaCI, and hydrolysis was measured for 30 minutes at 37°C. In experiments comparing the rates of hydrolysis of N-benzoyl-Z-arginine, N-a-acetyl-Zlysine, and a-tosyl-Mysine methyl esters with that of p-toluenesulfonyl-J-arginine methyl ester, the concentration of substrate was 0.015M.
To measure the effect of partially purified HF on the generation of kaolin-activated p-toluenesulfonyl-Jarginine methyl esterase activity, 0.025 ml of highpurity HF (1 unit/ml) was mixed with 0.1 ml of kaolin suspension (10 mg/ml) in 12 X 75-mm polystyrene tubes, and 0.1 of ml Fletcher trait or HFdeficient plasma was then added to each tube. At intervals, during incubation at 25°C, 2 ml of ice-cold 0.05M p-toluenesulfonyl-Z-arginine methyl ester was added and hydrolysis was measured as described previously. As a control, the esterase activity was also measured in a mixture of HF and kaolin.
The effect of HF-deficient plasma on the generation of kaolin-activated p-toluenesulfonyl-Z-arginine methyl esterase activity in Fletcher trait plasma was tested in mixtures of different proportions of HFdeficient and Fletcher trait plasma in which the esterase was generated with kaolin.
Kinin activity was measured on an isolated estrus rat uterus in an 8-ml organ bath containing de Jalon's mixture (20) kept at 29-31°C. Contraction of the muscle was recorded electrically with a linear transducer (Phipps and Bird) and a recorder (Bausch and Lomb, model VOM-5). When a 2-cm segment of uterine horn was used, this assay was about a hundredth as sensitive to kinin as the assay employing an intact muscle. Unless otherwise noted, an intact muscle trimmed proximally to fit the organ bath was used.
To measure the rate of kinin formation in undiluted plasma continuously agitated with powdered Pyrex (20 mg acid-washed powdered Pyrex [100 mesh]/ ml plasma) in polystyrene tubes, sequential samples were applied to the assay muscle. The muscle was observed for contractile activity for at least 60 seconds thereafter.
Kallikrein in plasma was also activated by treatment with acetone according to the procedure used by Webster and Pierce (21) . Trypsin (crystalline, salt-free) was used in a concentration of 50 /Ag/ml incubation mixture to measure kininogen in unfractionated heated plasma.
To measure the effect of HF fragments on kinin formation in normal, HF-deficient, PTA-deficient, or Fletcher trait plasma, 0.1 ml of test plasma, 0.1 ml of 0.01M o-phenanthroline, 0.05 ml of HF fragments or barbital-saline buffer, and 0.7 ml of barbital-saline buffer were mixed in a 10 X 75-mm polystyrene tube at 37°C. After 2 minutes, 0.05-ml samples were tested on an estrus rat uterus.
Crude plasma kallikrein was generated by incubating 1.2 ml of crude plasma prekallikrein with 3 mg of Enzite-trypsin at37°C for 30 minutes with occasional shaking. The supernatant fluid (kallikrein) was separated from the Enzite-trypsin by centrifugation. Crude plasma kallikrein had no caseinolytic activity.
The effect of lima-bean trypsin inhibitor, soybean trypsin inhibitor, and Trasylol on the kallikreinlike activity of Enzite-trypsin-treated crude prekallikrein was tested by incubating 0.1 ml of test material with 0.1 ml of lima-bean trypsin inhibitor (1 mg/ml), soybean trypsin inhibitor (1 mg/ml), Trasylol (1,000 klU/ml), or barbital-saline buffer at 37°C for 5 minutes in 10 X 75-mm polystyrene tubes. Then, 0.05 ml of 0.01M o-phenanthroline, 0.05 ml of crude kininogen, and 0.2 ml of barbital-saline buffer were added and the mixtures were incubated at 37°C for 12 minutes. Samples (0.1 ml) were tested for kinin on the uterine muscle.
Results
STUDIES ON THE GENERATION OF ESTEROLYTIC ACTIVITY IN FLETCHER TRAIT PLASMA
Esterolytic activity directed at p-toluenesulfonyl-Z-arginine methyl ester evolves when normal plasma is incubated with kaolin (19) . In the present study, esterolysis by normal plasma was maximal within 1 minute of incubation and gradually decreased to half of the maximal activity after 10 minutes ( Fig. 1A ). Under the same conditions, no esterolysis occurred when Fletcher trait plasma was incubated with kaolin for 10 minutes; however, significant esterolytic activity, (approximately one-fifth of the maximum evolved with normal plasma) was found after 20-30 minutes. No esterolytic activity was detected when HF-deficient plasma was incubated with kaolin for 60 minutes. The source of the esterolytic properties generated in Fletcher trait plasma was unclear. The esterolytic activity in Fletcher trait plasma incubated with kaolin for 30 minutes was tested A: Kaolin activation of plasma p-toluenesulfonyl-l-arginine methyl esterase activity in normal, Fletcher trait, or HFdeficient plasma. Plasma (0.15 ml) and kaolin suspension (0.15 ml, 10 mglml 0.1M sodium phosphate buffer, pH 7.5, in 0.15M NaCl) were incubated at 25°C in 12 x 75-mm polystyrene tubes. At intervals, 0.2-ml samples were transferred into 12 x 100-mm glass tubes containing 2.0 ml of 0.05M p-toluenesulfonyl-l-arginine methyl ester in 0.1M sodium phosphate buffer (pH 7.5) in 0.15M NaCl. Esterase activity was measured as described in Methods. B: Effect of the addition of partially purified HF on the generation of p-toluenesulfonyl-l-arginine methyl esterase activity in Fletcher trait or HF-deficient plasma. High-purity HF (0.025 ml, 1 unit/ml) was added to 0.1 ml of kaolin suspension (10 mglml) in 12 x 75-mm polystyrene tubes; 0.1 ml of Fletcher trait or HF-deficient plasma was then added to each tube and incubated at 25°C. At intervals, 2-ml of ice-cold 0.05M p-toluenesulfonyl-l-arginine methyl ester was added and esterase activity was measured as described in Methods. C: Kaolin activation of plasma p-toluenesulfonyl-l-arginine methyl esterase activity in the mixtures of Fletcher trait with normal or HF-deficient plasma. Mixtures (0.1 ml) of Fletcher trait with normal or HF-deficient plasma (1:1) were incubated with 0.1 ml of kaolin suspension (10 mglml 0.1M sodium phosphate buffer, pH 7.5, in 0.15M NaCl) in 12 x 75mm polystyrene tubes at 25°C. At intervals, 2 ml of ice-cold 0.05M p-toluenesulfonyl-l-arginine methyl ester was added to the tubes and esterase activity was measured as described in Methods.
on several synthetic substrates. The relative ratios of the digestion of IV-a-acetyl-Mysine, a-tosyl-Mysine, or N-benzoyl-£-arginine methyl ester compared with that of p-toluenesulfonyl-Jarginine methyl ester were similar to those evoked by partially purified plasma kallikrein. Furthermore, Celite eluates prepared from oxalated Fletcher trait plasma contained esterase activity with avidity to these methyl esters similar to that of plasma kallikrein. The esterolytic activity in Celite eluates was not associated with fibrinolytic or thrombin activity.
The defective generation of esterolytic activity in Fletcher trait plasma could not be attributed to deficient activation of HF. When HF-deficient plasma was incubated with kaolin and highpurity HF, it developed esterolytic properties in a manner similar to normal plasma (Fig. IB) . In contrast, the addition of kaolin and even a fivefold increment in HF to Fletcher trait plasma did not repair defective generation of esterolytic activity, even though a small amount of activity was demonstrable within 10 minutes.
Impaired generation of esterolytic properties in Fletcher trait plasma seemed to be related to the functional deficiency of a necessary reactant Plasma mixtures were shaken with 20 mg Pyreximl mixture for the time intervals noted on the abscissa. EDTA (0.01M) was included in the mixtures activated in this way; at the time intervals noted, samples were transferred to an equal volume of soybean trypsin inhibitor (1.0 mglml) and EDTA to give a final concentration ofO.OlM. In this way, kinin generation was stopped by the soybean trypsin inhibitor at the time intervals noted, and the kinin already generated was preserved by the EDTA. At each time interval, muscle contractions were induced by comparable volumes of each plasma mixture.
rather than to the presence of an inhibitor. The amount of p-toluenesulfonyl-J-arginine methyl esterase activity generated at 1 minute when Fletcher trait plasma and normal plasma were separately exposed to kaolin and then combined was the same as that when a mixture of equal parts of each plasma was incubated with kaolin. When mixtures of 95% Fletcher trait plasma and 5% HF-deficient plasma were incubated with kaolin, the delay until esterolytic activity evolved was shortened to 5 minutes, but the maximal activity generated after 20-30 minutes was no greater than that found in mixtures lacking HF-deficient plasma. In mixtures of 20% HF-deficient plasma and 80% Fletcher trait plasma, only a trace of activity evolved within 1 minute. When Fletcher trait plasma was incubated with an equal volume of normal or HF-deficient plasma, maximal esterolytic activity developed within 1 minute, but the activity was half that which developed in identically treated normal plasma (Fig. 1C ). After 10 minutes, however, the rate of hydrolysis of p-toluenesulfonyl-Z-arginine methyl ester by Fletcher trait plasma mixed with normal or HFdeficient plasma was almost the same as that by normal plasma alone. Therefore, Fletcher trait plasma seems to be functionally deficient in agents required for the immediate generation of p-toluenesulfonyl-Z-arginine methyl esterase activity but not in agents required for the activity which is evolved more gradually or for the activity present in Celite eluates.
STUDIES ON KININ FORMATION IN FLETCHER TRAIT PLASMA
Kinin did not form when Fletcher trait plasma was shaken with powdered Pyrex. When normal plasma was identically treated, kinin activity appeared within 2 minutes and was then inactivated within 10 minutes by the kininase activity of plasma. Fletcher trait plasma developed no kinin activity even after a 30-minute exposure to Pyrex. Failure of kinin generation in Fletcher trait plasma was not due to a deficiency of kininogen, because the kinin released when Fletcher trait plasma was incubated at 61°C for 60 minutes and then incubated with trypsin was comparable to that released from heated normal plasma. The absence of kinin generation in glass-treated Fletcher trait plasma also was not due to rapid destruction of kinin: addition of 2.5 mg EDTA/ml (an amount which inhibits plasma kininases) prevented the inactivation of kinin generated in normal plasma incubated with glass but did not reveal kinin formation in Fletcher trait plasma. Moreover, the rate of inactivation of synthetic bradykinin by citrated Fletcher trait plasma and by normal plasma was about the same.
Fletcher trait plasma did not block kinin release in normal or HF-deficient plasma. The rate of kinin formation during Pyrex treatment of plasma mixtures progressively increased as the proportion of normal or HF-deficient plasma added to Fletcher trait plasma was increased (Fig. 2) . When a mixture contained equal amounts of normal and Fletcher trait plasma, Test plasma (0.1 ml) was incubated with 0.1 ml of 0.01M o-phenanthroline, 0.05 ml of HF fragments or barbitalsaline buffer, and 0.7 ml of barbital-saline buffer in 10 X 75mm polystyrene tubes at 37°C. After 2 minutes, a 0.05-ml sample was transferred to the uterine muscle bath, and the muscle contraction was measured. No generation of kinins could be demonstrated in the mixture of Fletcher trait plasma and HF fragments even after incubation for 10 minutes. This experiment was performed with a segment of uterine muscle, which is less sensitive to kinin than an intact muscle.
kinin evolved as it does in normal plasma alone; however, kinin release in mixtures of equal amounts of HF-deficient and Fletcher trait plasma remained impaired (Fig. 2) .
Generation of kinin in plasma exposed to glass can be mediated through the activation of HF (1) . Acetone activation of plasma prekallikrein is dependent on the presence of HF (22).
After treatment with acetone, normal plasma contained kinin activity and released kinin from crude kininogen, but Fletcher trait plasma had neither of these properties. Nonetheless, defective kinin generation in Fletcher trait plasma was not due to a failure to activate HF. No kinin evolved in a mixture of ellagic acid-activated, low-purity HF during incubation with Fletcher trait plasma for 20 minutes, although maximal kinin activity evolved in mixtures of the activated HF with normal or HF-deficient plasmas within 2 minutes. Even when Fletcher trait plasma was diluted a hundredfold and ellagic acidactivated HF was added, no kinin was identified in a series of samples tested every 2-5 minutes for 1 hour. However, when Fletcher trait plasma was mixed with an equal volume of normal or HF-deficient plasma before exposure to ellagic acid-treated HF, the rate of kinin generation was normal. These experiments suggest that defective kinin release in Fletcher trait plasma is not related to a faulty activation of HF but rather to an impaired response to activated HF. Several additional experiments confirm this view. Pyrex glass powder, incubated with low-purity HF and then washed, readily generated kinin in normal plasma but not in Fletcher trait plasma even after 35 minutes. Furthermore, HF fragments (10-12) prepared by tryptic digestion of high-purity HF induced activity in normal, HF-deficient, and PTA-deficient plasma but not in Fletcher trait or heated normal plasma ( Table   1 ).
The failure of activated HF or HF fragments to induce kinin release in Fletcher trait plasma might be related to either a functional deficiency 
Kinin-Forming Activity of QAE-Sephadex-Adsorbed, Enzite-Trypsin-Treated Plasma
Sample Normal plasma PTA-deficient plasma HF-deficient plasma Fletcher trait plasma Bradykinin (100 ng/ml) alone Kininogen alone QAE-Sephadex-adsorbed, Enzite-trypsin-treated plasma (0.1 ml) was incubated with 0.05 ml of 0.01M o-phenanthroline, 0.05 ml of kininogen or barbital-saline buffer, and 0.3 ml of barbital-saline buffer in 10 x 75-mm polystyrene tubes at 37°C. After 12 minutes, 0.1-ml or 0.2-ml samples were transferred to the uterine muscle bath and the muscle contraction was measured as described in Methods. This experiment was performed with a segment of uterine muscle rather than an intact muscle. of plasma prekallikrein or an impairment of the mechanism which converts plasma prekallikrein to kallikrein. When crude plasma prekallikrein fractions were incubated with Enzite-trypsin, those prepared from normal, HF-deficient, or PTA-deficient plasma acquired the ability to release kinin from kininogen. No kinin activity was demonstrated when identically treated fractions of Fletcher trait plasma were tested ( Table 2 ). Kinin formation by trypsin-treated prekallikrein fractions of normal or HF-deficient plasma was inhibited by soybean trypsin inhibitor or Trasylol but not by lima-bean trypsin inhibitor. These results indicate that the kininreleasing activity was probably due to a plasma kallikrein.
A KININ-GENERATING FRACTION OF FLETCHER TRAIT PLASMA
Although these experiments suggest that Fletcher trait plasma is functionally deficient in a prekallikrein, other experiments reveal that this plasma contains the precursor of a kiningenerating enzyme. When Celite eluates were incubated with crude kininogen (heated plasma), those eluates prepared from citrated or oxalated Fletcher trait plasma generated as much kinin activity as those prepared from normal plasma ( Table 3) . When Celite eluates derived from normal, HF-deficient or Fletcher trait plasma were incubated with crude kininogen, increasing amounts of kinin evolved; this kinin was destroyed by small amounts of carboxypeptidase B (Table 4 ) but was not affected by 10~5M lysergic acid diethylamide in the assay bath. Soybean trypsin inhibitor blocked the release of kinin from crude kininogen by Celite eluates derived from normal or Fletcher trait plasma to a comparable degree.
Dialyzed Celite eluates derived from Fletcher trait plasma alone induced muscular contraction (Table 3) , as if they contained kininogen as well as kinin-generating enzymes. Celite eluates In experiment A, eluates diluted 1.5 times with respect to starting plasma volume were incubated with an equal volume of buffer or crude kininogen at 26°C for 10 minutes before samples of 0.01-0.03 ml were tested for kinin activity. In experiment B, Celite eluates, twice concentrated with respect to starting plasma, were applied directly to the assay muscle without prior incubation. In experiment C, a volume of Celite eluate was applied to the assay muscle without prior incubation. When the volume applied failed to induce a contraction within 60 seconds, crude kininogen was added. The resulting contractions reflect kinin release from the kininogen by the Celite eluate in the assay mixture. The eluate from Fletcher trait plasma used in this experiment was a different preparation than used in experiment B; it was dissolved in a volume of barbital-saline buffer equal to the volume of plasma from which the eluate was derived. The eluate from normal plasma was twice concentrated with respect to starting volume. Eluates from Celite treated with citrated normal or Fletcher trait plasma, in solutions with volumes equal to those of the starting plasma samples, were dialyzed against multiple changes of barbital-saline buffer (500 ml buffer/2 ml eluate). Then, 0.25 ml of eluate was mixed with 0.002 ml of lima-bean trypsin inhibitor (10 mg/ml) and 0.18 ml of partially purified kininogen in silicone-coated tubes at 37°C. At the intervals shown, samples were tested for kinin activity in an assay bath containing lima-bean trypsin inhibitor (160 ^tg/ml). After 60 minutes, each mixture was placed in a boiling water bath for 10 minutes, cooled, and retested for kinin. Since activity was still present, the residual mixtures were incubated with carboxypeptidase B (108 uglml mixture) at 37°C for 10 minutes and retested. The sensitivity of the assay muscle used in each experiment to bradykinin is shown in the last 2 lines of the table.
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"This experiment was done separately using a less sensitive assay muscle than the one used to test kinin-generating capacity of Celite eluates of normal and Fletcher trait plasma. derived from normal plasma had similar properties in lower concentration. In other experiments, Celite eluates from Fletcher trait plasma were shown to contain 20 times as much trypsininducible kinin activity as Celite eluates from normal plasma. The kinin-generating properties of Celite eluates could not be attributed to plasmin, which releases kinin from plasma substrate, since the eluates did not digest bovine fibrin. Adjustment of the pH of plasma samples from 7.0 to 7.4 before Celite treatment did not alter the evolution of kinin-generating activity in the final eluates.
Possibly, traces of prekallikrein remaining in crude kininogen were converted to kallikrein by activated HF in Celite eluates from Fletcher trait plasma. Crude kininogen, which developed no kinin activity during incubation with partially purified activated HF did form kinin on incubation with Celite eluates from Fletcher trait plasma. In addition, partially purified kininogen developed kinin activity during incubation with Celite eluates from normal or Fletcher trait plasma (Table 4 ). Celite eluates from the HFdeficient plasma also released kinin from this kininogen in a comparable experiment done separately (Table 4) , as reported by Ozge-Anwar et al. (23) . Kinin release was inhibited by soybean trypsin inhibitor but not by lima-bean trypsin inhibitor (Table 4 ). In each instance, the kinin which evolved was stable at 100°C for 10 minutes and inactivated by carboxypeptidase B (Table 4 ). Thus, each eluate contained a kallikreinlike substance.
Celite eluates prepared from citrated Fletcher trait plasma digested p-toluenesulfonyl4arginine methyl ester even more readily (50 /xM/min) than did identical eluates prepared from HF-deficient (30 /u.M/min) or normal (25 /i,M/min) plasma. Since Celite eluates contain many agents, their esterolytic properties need not result from the activity of a plasma kallikrein alone.
INHIBITION OF KININ RELEASE BY PLASMA
In earlier studies, Fletcher trait plasma inhibited the clot-promoting properties of glass (24). Similarly, powdered Pyrex glass shaken with Fletcher trait plasma and then washed no longer induced kinin formation when it was shaken with fresh normal plasma ( Table 5) . Pyrex identically treated with normal plasma generated kinin activity in fresh normal plasma after a delay ( Powdered Pyrex glass (20 mg), untreated or previously shaken with either 1 ml of normal or Fletcher trait plasma for 6-8 minutes and washed ten times with 3 ml of cold barbitalsaline buffer, was added to fresh pooled normal plasma; samples (0.01 ml) were then applied to the assay muscle at the times noted during continuous shaking of the plasma-Pyrex mixture in polystyrene tubes. plasma was found. The addition of Fletcher trait plasma to a mixture of normal plasma and Pyrex which had already developed kinin activity did not noticeably inhibit the kinin. Thus, although surface activation of normal plasma was blocked by preliminary treatment of Pyrex with Fletcher trait plasma, the Fletcher trait plasma did not inhibit kinin already generated.
Discussion
In these experiments, Fletcher trait plasma was unable to generate arginine esterase and kinin on exposure to agents known to activate HF or to already activated HF. The development of coagulant, permeability enhancing, and fibrinolytic activity in Fletcher trait plasma through mechanisms dependent on activation of HF was also impaired (6-8).
Colman et al. (25) have reported that kaolinactivated p-toluenesulfonyl-i-arginine methyl esterase activity in normal plasma is due mainly to a plasma kallikrein generated from a prekallikrein by activated HF. In assays similar to theirs, unfractionated Fletcher trait plasma developed esterolytic properties only after an abnormally long delay and in amounts significantly less than those in normal plasma. The deficient generation of esterolytic activity was not due to failure to evolve activated HF or to the presence of inhibitors which affected either the evolution or the expression of esterolytic properties. Rather, unfractionated Fletcher trait plasma seemed to be functionally deficient in agents needed for the rapid generation of p-toluenesulfonyl-Z-arginine methyl esterase activity. The nature of the esterase which evolved after Fletcher trait plasma was incubated for protracted periods or in Celite eluates derived from Fletcher trait plasma was unclear. However, the potent esterolytic properties of Celite eluates derived from Fletcher trait plasma could not be identified with thrombin or plasmin. Even though the relative rates at which several synthetic amino acid esters were hydrolyzed were similar to those of plasma kallikreininduced hydrolysis, both plasma and Celite eluates could contain other esterolytic agents. Thus, direct proof that the esterase was a kallikrein was not obtained. Some esterase activity formed during contact activation of unfractionated Fletcher trait plasma, but this activity was not associated with kinin release, which did not occur even during prolonged exposure to glass.
Absence of kinin release during prolonged incubation of unfractionated Fletcher trait plasma with glass was not the result of impaired activation of HF, a deficiency of kininogen (the precursor of kinins), or the excessive destruction of kinins. Instead, Fletcher trait plasma seemed to be functionally and antigenically deficient (8) in a plasma prekallikrein which requires activated HF for its activation, as reported by Wuepper (6) , and by Weiss et al. (7) .
This hypothesis cannot explain the kiningenerating activity in Celite eluates derived from Fletcher trait plasma, which closely resembles that in eluates from normal plasma. Both types of eluate released kinin from partially purified kininogen equally well. Also, soybean trypsin inhibitor but not lima-bean trypsin inhibitor blocked this action; this result suggests that both eluates contained kallikreinlike activity. Perhaps, the plasma of individuals with Fletcher trait contains a form of prekallikrein, antigenically distinct from that recognized by our antiserum and susceptible to activation by Celite 
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but not to activation by activated HF or trypsin. Alternatively, individuals with Fletcher trait may lack one of several prekallikreins present in normal plasma.
Faulty generation of contact-mediated clotting, fibrinolysis, and permeability enhancement in Fletcher trait plasma (6-8) was considered by Cochrane and coworkers (26) to be due to the deficiency of a prekallikrein which when activated could then activate HF. However, Wuepper and Cochrane (27) failed to shorten the partial thromboplastin time of normal human noncontact plasma with a human kallikrein, and we could not directly activate partially purified HF with partially purified human kallikrein (8) . Therefore, during clotting, the kallikrein may function as a co-factor for activated HF rather than as a factor in its activation. The partial correction of abnormal clotting, fibrinolysis, and permeability enhancement when activated HF is added to Fletcher trait plasma (8) is consistent with this possibility. Esterolytic properties and kinin-releasing activity in unfractionated Fletcher trait plasma, however, were not restored by activated HF. This observation suggests that a prekallikrein which reacts with the activated HF is deficient or obscured in this plasma. HF-deficient plasma appears to contain a prekallikrein which does not require activated HF for its activation, since Celite eluates derived from HF-deficient plasma also contained kallikreinlike activity (23).
Previous exposure to plasma inhibited the capacity of Pyrex to generate kinins; this inhibitory property was more evident when the glass was exposed to Fletcher trait plasma than when it was exposed to normal plasma. These experiments indicate a quantitative but not a qualitative difference in the inhibitory activities in Fletcher trait and normal plasmas. Earlier, we found that Fletcher trait plasma inhibited the clot-promoting properties of glass (24). The deficient kinin-generating capacity in unfractionated Fletcher trait plasma might secondarily allow the expression of more inhibitory activity by this plasma than by normal plasma.
